Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi companyKER-0193, a novel, orally bioavailable…
THIRUVANANTHAPURAM, India, Aug. 18, 2025 /PRNewswire/ -- The first phase of the International Institute of People with Disabilities (IIPD) in…